Thus, lower drug uptake or high drug extrusion may create a favorable environment for CML cells acquiring other resistance mechanisms, such as BCR-ABL1 mutations [23,111]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.